Skip to main navigation
Logo

Press Releases

Press Releases

Date Title View
March 21, 2022 Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 8, 2022 Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
March 7, 2022 Caribou Biosciences to Present at Upcoming Investor Conferences
February 7, 2022 Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference
January 18, 2022 Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer
January 4, 2022 Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2

 

 


Toolkit

Print Page

Email Alerts

RSS Feeds

Investor Contact

Main Menu

  • News & Events
    • Press Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Results
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR
  • More
    • About
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
      • Collaborations
      • Licenses
    • Technology
      • Allogeneic T cells
      • Allogeneic NK cells
      • chRDNAs
      • Publications
    • Pipeline
      • T cell pipeline
      • NK cell pipeline
      • Clinical Trials
    • Careers
      • Job Opportunities
      • Values
      • Spotlights
      • Benefits
        • Summary of Benefits
    • Investors
      • News & Events
        • Press Releases
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Corporate Governance
        • Documents & Charters
        • Leadership
        • Board of Directors
        • Committee Composition
      • Financials & Filings
        • SEC Filings
        • Annual Reports
        • Quarterly Results
      • IR Resources
        • FAQs
        • Email Alerts
        • Contact IR
    • Contact

    Main Menu

    • About
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
      • Collaborations
      • Licenses
    • Technology
      • Allogeneic T cells
      • Allogeneic NK cells
      • chRDNAs
      • Publications
    • Pipeline
      • T cell pipeline
      • NK cell pipeline
      • Clinical Trials
    • Careers
      • Job Opportunities
      • Values
      • Spotlights
      • Benefits
        • Summary of Benefits
    • Investors
      • News & Events
        • Press Releases
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Corporate Governance
        • Documents & Charters
        • Leadership
        • Board of Directors
        • Committee Composition
      • Financials & Filings
        • SEC Filings
        • Annual Reports
        • Quarterly Results
      • IR Resources
        • FAQs
        • Email Alerts
        • Contact IR
    • Contact

    logo

    Caribou Biosciences, Inc.
    2929 7th Street, Suite 105
    Berkeley, CA 94710
    Tel: 510-982-6030
    info@cariboubio.com

    ©  Caribou Biosciences, Inc. All rights reserved.

    02. Footer Copyright Links

    • Privacy Policy
    • Terms of Use

    03. Footer Social Links

    • Twitter
    • linkedin